The top opportunities in the GLP-1 receptor agonist markets segmented by end users will arise in the hospitals segment, which will gain $43,597.5 million of global annual sales by 2030
Doctor-led treatment instead of automated programs: Unlike online platforms or cookie-cutter clinics, your treatment here is guided by a licensed physician
This triggers a cascade of beneficial effects such as increased insulin secretion, improved glucose uptake, and a sensation of satiety, making them valuable in managing metabolic disorders like diabetes and obesity
Retatrutide is a next-generation weight loss injection developed by Eli Lilly (same manufacturer as Mounjaro), designed to target three separate hormone receptors in the body: the GLP-1 receptor, the GIP receptor, and the glucagon receptor
They can help determine if the medication is appropriate and which prescription option is best given your health status